Universal Beteiligungs und Servicegesellschaft mbH Purchases 19,166 Shares of Natera, Inc. $NTRA

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 15.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,802 shares of the medical research company’s stock after buying an additional 19,166 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Natera were worth $22,504,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SWS Partners lifted its stake in Natera by 11.8% during the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Natera by 192.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after buying an additional 5,614 shares in the last quarter. Baird Financial Group Inc. raised its holdings in shares of Natera by 277.8% during the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after buying an additional 19,576 shares in the last quarter. Orion Porfolio Solutions LLC lifted its position in shares of Natera by 68.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after buying an additional 4,946 shares during the last quarter. Finally, Park Avenue Securities LLC acquired a new stake in Natera in the second quarter valued at about $1,525,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high‑value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high‑profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near‑term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

Natera Price Performance

NTRA opened at $242.91 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The company’s 50 day moving average price is $233.44 and its two-hundred day moving average price is $190.60. The firm has a market capitalization of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the business posted ($0.26) EPS. Natera’s revenue was up 34.7% on a year-over-year basis. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the completion of the transaction, the chief executive officer directly owned 144,816 shares in the company, valued at $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roelof Botha sold 75,000 shares of Natera stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the transaction, the director directly owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 514,562 shares of company stock worth $114,292,421 over the last 90 days. Company insiders own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Citigroup assumed coverage on shares of Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a research report on Monday, October 27th. Piper Sandler raised their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, Stephens boosted their target price on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.